[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:neurofibromatosis-type-1":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":170,"states":175},"Neurofibromatosis Type 1",26,21,[8,16,22,28,35,41,48,54,60,66,72,78,84,90,96,102,108,114,120,125,131,137,144,150,158,164],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07102394","Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1",[12],"Phase 1","RECRUITING","2026-08-26T02:17:53.433613Z","2026-05-05T02:43:28.130062Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06502171","Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas",[12],"2026-08-26T02:17:40.683658Z","2026-05-05T02:43:27.752091Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06961565","PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",[12],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:27.513386Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06188741","Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1",[32],"Phase 2","2026-08-26T02:18:25.327036Z","2026-05-05T02:43:27.426581Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06541847","A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1",[32],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:27.317314Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT04750928","Cyclin-Dependent Kinase (CDK)4\u002F6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas",[45],"Phase 1\u002FPhase 2","2026-08-26T02:16:05.813655Z","2026-05-05T02:43:27.316168Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06159166","Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).",[45],"2026-08-26T02:17:59.904383Z","2026-05-05T02:43:27.308579Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06735820","Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST",[45],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:28.869744Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05849662","A Phase I\u002FII Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia",[45],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:28.528927Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05253131","Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas",[32],"2026-08-26T02:15:37.042762Z","2026-05-05T02:43:27.251035Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06880991","Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study",[],"2026-08-26T02:17:39.048487Z","2026-05-13T02:55:06.588057Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT02544022","Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.096968Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06515860","Neurofibromatosis Type 1 Tumor Early Detection Study",[],"2026-08-03T02:47:17.144574Z","2026-05-13T02:55:06.496843Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06222203","Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)",[],"2026-08-26T02:18:21.216897Z","2026-05-13T02:55:06.427261Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT01885767","Neurofibromatosis (NF) Registry Portal",[],"2026-08-26T02:17:06.985283Z","2026-05-13T02:55:06.078734Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT04395495","RASopathy Biorepository",[],"2026-08-26T02:18:26.932189Z","2026-05-13T02:55:06.251994Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT03050268","Familial Investigations of Childhood Cancer Predisposition",[],"2026-08-26T02:17:18.747857Z","2026-05-13T02:55:06.107926Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06507748","A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)",[],"2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.756132Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":39,"content_modified":124},"NCT07233408","Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy",[],"2026-05-05T02:43:26.664459Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT04763109","Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence",[],"2026-08-26T02:17:22.949982Z","2026-04-29T02:57:57.142375Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT05361811","Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial",[],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:27.038026Z",{"nct_id":138,"title":139,"phases":140,"status":141,"updated_at":142,"content_modified":143},"NCT05238909","Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1",[],"ENROLLING_BY_INVITATION","2026-08-26T02:19:10.436356Z","2026-06-16T05:54:08.026991Z",{"nct_id":145,"title":146,"phases":147,"status":141,"updated_at":148,"content_modified":149},"NCT06300502","Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)",[12],"2026-08-26T02:16:22.235886Z","2026-06-16T05:54:07.723494Z",{"nct_id":151,"title":152,"phases":153,"status":155,"updated_at":156,"content_modified":157},"NCT03975829","Pediatric Long-Term Follow-up and Rollover Study",[154],"Phase 4","ACTIVE_NOT_RECRUITING","2026-08-03T01:58:01.892442Z","2026-05-13T02:55:06.182080Z",{"nct_id":159,"title":160,"phases":161,"status":155,"updated_at":162,"content_modified":163},"NCT06104488","A Study of Avutometinib for People With Solid Tumor Cancers",[12],"2026-08-03T02:10:11.726086Z","2026-05-05T02:43:26.917842Z",{"nct_id":165,"title":166,"phases":167,"status":155,"updated_at":168,"content_modified":169},"NCT06262113","A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1",[],"2026-08-03T02:11:30.522963Z","2026-05-05T02:43:27.337106Z",[171],{"biomarker":172,"count":173,"slug":174},"NF1 Gene",4,"nf1-gene",[176,180,184,188,191,195,198,201,204,207,210,213,217],{"state":177,"count":178,"slug":179},"Maryland",12,"maryland",{"state":181,"count":182,"slug":183},"District of Columbia",8,"district-of-columbia",{"state":185,"count":186,"slug":187},"Massachusetts",7,"massachusetts",{"state":189,"count":186,"slug":190},"Ohio","ohio",{"state":192,"count":193,"slug":194},"Alabama",5,"alabama",{"state":196,"count":193,"slug":197},"Illinois","illinois",{"state":199,"count":193,"slug":200},"New York","new-york",{"state":202,"count":193,"slug":203},"Pennsylvania","pennsylvania",{"state":205,"count":193,"slug":206},"Texas","texas",{"state":208,"count":173,"slug":209},"California","california",{"state":211,"count":173,"slug":212},"Indiana","indiana",{"state":214,"count":215,"slug":216},"Missouri",3,"missouri",{"state":218,"count":215,"slug":219},"Tennessee","tennessee"]